Replies to post #20722 on Ariad Pharmaceuticals Inc fka ARIA

[ariadndndough]

don correct me if i am wrong but from this article the sweet spot for 113 hopefully is this correct??

We further identified a subset (3/50; 6%) of treatment naive NSCLC patients with ALK rearrangements that also had concurrent EGFR activating mutations. Our studies identify resistance mechanisms to ALK TKIs mediated by both ALK and by a bypass signaling pathway mediated by EGFR. These mechanisms can occur independently, or in the same cancer, suggesting that the combination of both ALK and EGFR inhibitors may represent an effective therapy for these subsets of NSCLC patients.